Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$133M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$93.9M |
| 4 |
Amazon
AMZN
|
+$91.8M |
| 5 |
Otis Worldwide
OTIS
|
+$84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$226M |
| 2 |
RTN
Raytheon Company
RTN
|
+$145M |
| 3 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$51.2M |
| 4 |
Newmont
NEM
|
+$50.7M |
| 5 |
Yum! Brands
YUM
|
+$33.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.6% |
| 2 | Healthcare | 15.16% |
| 3 | Consumer Discretionary | 12.49% |
| 4 | Communication Services | 10.41% |
| 5 | Industrials | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CALA
2351
DELISTED
Calithera Biosciences, Inc
CALA
| $572K | ﹤0.01% |
+5,415
| New | +$643K |
|
|
OGI
2352
Organigram Holdings
OGI
$177M
| $571K | ﹤0.01% |
92,000
+17,025
| +23% | +$115K |
|
2353
Hyster-Yale Materials Handling
HY
$621M
| $564K | ﹤0.01% |
14,600
+2,300
| +19% | +$85.7K |
|
2354
Expro Ltd
XPRO
$2.07B
| $562K | ﹤0.01% |
41,983
+13,233
| +46% | +$178K |
|
2355
Franklin Covey
FC
$227M
| $561K | ﹤0.01% |
26,200
+7,500
| +40% | +$152K |
|
|
ACBI
2356
DELISTED
Atlantic Capital Bancshares, Inc. Common Stock
ACBI
| $561K | ﹤0.01% |
46,100
+3,600
| +8% | +$41.3K |
|
|
AKRO
2357
DELISTED
Akero Therapeutics
AKRO
| $558K | ﹤0.01% |
+22,400
| New | +$512K |
|
2358
Astronics
ATRO
$4.61B
| $557K | ﹤0.01% |
63,306
+9,480
| +18% | +$74.1K |
|
2359
SunCoke Energy
SXC
$783M
| $553K | ﹤0.01% |
186,950
+18,700
| +11% | +$59.7K |
|
|
TRUE
2360
DELISTED
TrueCar
TRUE
| $553K | ﹤0.01% |
214,200
+51,600
| +32% | +$132K |
|
2361
KRONOS Worldwide
KRO
$974M
| $550K | ﹤0.01% |
52,800
+8,400
| +19% | +$78.8K |
|
2362
Boston Omaha
BOC
$431M
| $547K | ﹤0.01% |
34,163
+17,363
| +103% | +$290K |
|
2363
Capital City Bank Group
CCBG
$901M
| $547K | ﹤0.01% |
26,100
+2,100
| +9% | +$41.2K |
|
|
CIVI
2364
DELISTED
Civitas Resources
CIVI
| $545K | ﹤0.01% |
36,800
+7,200
| +24% | +$117K |
|
2365
Village Super Market
VLGEA
$634M
| $543K | ﹤0.01% |
19,600
+3,100
| +19% | +$74.5K |
|
2366
Five Point Holdings
FPH
$373M
| $541K | ﹤0.01% |
117,700
+17,700
| +18% | +$89K |
|
2367
Dillards
DDS
$9.48B
| $536K | ﹤0.01% |
20,800
+500
| +2% | +$14.1K |
|
2368
Ribbon Communications
RBBN
$381M
| $535K | ﹤0.01% |
136,174
+28,800
| +27% | +$105K |
|
|
LCI
2369
DELISTED
Lannett Company, Inc.
LCI
| $535K | ﹤0.01% |
18,425
+2,975
| +19% | +$92.5K |
|
2370
Phathom Pharmaceuticals
PHAT
$731M
| $530K | ﹤0.01% |
+16,100
| New | +$619K |
|
|
LORL
2371
DELISTED
Loral Space and Communications, Inc.
LORL
| $525K | ﹤0.01% |
26,900
+4,300
| +19% | +$80.5K |
|
2372
Revolve Group
RVLV
$1.7B
| $523K | ﹤0.01% |
35,200
+9,300
| +36% | +$122K |
|
2373
Stoke Therapeutics
STOK
$2.1B
| $522K | ﹤0.01% |
21,900
+6,300
| +40% | +$150K |
|
|
CNBKA
2374
DELISTED
Century Bancorp Inc/Mass
CNBKA
| $521K | ﹤0.01% |
6,700
+1,100
| +20% | +$76.8K |
|
|
AMAG
2375
DELISTED
AMAG Pharmaceuticals
AMAG
| $521K | ﹤0.01% |
68,157
+3,700
| +6% | +$28.3K |
|
Similar funds
Swiss National Bank's Q2 2020 Portfolio in Review
As of Q2 2020, Swiss National Bank held 2,599 positions worth $118B, up 26% from $94.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Swiss National Bank's Q2 2020 filing shows 119 new, 2,134 increased, 181 reduced and 161 closed positions. Its largest new stake was Otis Worldwide: 1,621,054 shares worth $92.2M. The largest sale was Allergan plc, an estimated $226M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q2 2020 buy was Otis Worldwide: 1,621,054 shares worth $92.2M.
- Swiss National Bank added most to Alibaba in Q2 2020, an estimated $133M increase.
- Swiss National Bank's biggest Q2 2020 reduction was Newmont, cutting an estimated $50.7M.
- Swiss National Bank fully exited Allergan plc in Q2 2020, selling an estimated $226M.
- Swiss National Bank's ten largest holdings make up 24% of its $118B portfolio in Q2 2020.
- Swiss National Bank opened 119 new positions and closed 161 in Q2 2020.
- Swiss National Bank's portfolio value rose 26% quarter-over-quarter to $118B.
Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.